Can a Two-Drug combo keep multiple myeloma at bay longer?
NCT ID NCT05271630
First seen Oct 31, 2025 · Last updated May 09, 2026 · Updated 30 times
Summary
This study looks at whether using two drugs (an immunomodulatory drug plus a proteasome inhibitor) as maintenance therapy after a stem cell transplant works better than one drug alone for people with multiple myeloma. The goal is to see if the combination can turn cancer markers from positive to negative and help keep the cancer from coming back. The study involves 69 adults who have already had a stem cell transplant as their first treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.